Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Highlightll Out-licenses Dual Inhibitor for Parkinson’s in $970 Million Deal

publication date: Mar 22, 2023

Hangzhou Highlightll Pharma out-licensed rights to its novel oral, brain-penetrating, dual inhibitor to New Haven’s Biohaven in a deal worth up to $970 million. The candidate is a small molecule dual TYK2/JAK1 inhibitor that is intended to treat autoimmune/inflammatory and CNS diseases. Biohaven will have global rights (ex-China) to BHV-8000 for $10 million upfront and $10 million in Biohaven equity, plus milestones of up to $950 million and tiered royalties. Neuro dysregulation of the immune system is implicated in chronic diseases including Parkinson's – Biohaven’s initial target – MS, Alzheimer's, ALS and autoimmune encephalitis. More details....

Stock Symbol: (NYSE: BHVN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital